The New England Journal of Medicine (NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It describes itself as the oldest continuously ...

Welcome and thank you for considering the New England Journal of Medicine (NEJM) as a venue for your work. As the oldest continuously-published medical journal, our mission since 1812 has been to ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a ...

The endTB trial is one of four recent randomized controlled trials testing new, shorter, and less toxic treatment regimens ...

Tuberculosis remains one of the deadliest infectious diseases worldwide, with drug-resistant strains posing a significant ...

Scientists have discovered three powerful new drug regimens that offer more effective treatment for tuberculosis—bringing ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...

Will the Super Bowl Ads Be Woke? Consequences for the International Criminal Court The International Criminal Court Has Put Itself at Trump’s Mercy Tinker, Tailor, Soldier, German Chancellor ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...